| Clarke, Ed |
| Active, not recruiting | 3 | 600 | RoW | 13-valent pneumococcal conjugate vaccine [Prevenar13®] plus tetanus toxoid, PCV13, placebo 0.9% sodium chloride plus tetanus toxoid, placebo, tetanus toxoid | London School of Hygiene and Tropical Medicine, WHO Pneumococcal Serology Reference Laboratory Institute of Child Health, BUGS Bioscience London Bioscience Innovation Centre 2 Royal College Street London | Pneumonia | 02/19 | 12/20 | | |
| Active, not recruiting | 3 | 200 | RoW | meningococcal serogroup A conjugate vaccine, MenAfriVacâ„¢. | London School of Hygiene and Tropical Medicine, Public Health England, Department of State for Health and Social Welfare, The Gambia, World Health Organization, University of Cambridge, Stanford University | Meningitis, Meningococcal | 10/20 | 08/21 | | |
NCT05447377: A Study of SII Yellow Fever Vaccine to Compare Safety and Immunogenicity With STAMARIL® In Healthy Infants |
|
|
| Recruiting | 3 | 2216 | RoW | SII Yellow Fever Vaccine, STAMARIL® | Serum Institute of India Pvt. Ltd. | Yellow Fever | 01/24 | 01/24 | | |
NCT03832049: HPV Vaccination in Africa- New Delivery Schedules Alias The HANDS HPV Vaccine Trial |
|
|
| Active, not recruiting | 3 | 1720 | RoW | 9-valent human papillomavirus vaccine (Gardasil 9) - 3 doses, 9-valent human papillomavirus vaccine (Gardasil 9) - 2 doses, 9-valent human papillomavirus vaccine (Gardasil 9) - 1 dose | London School of Hygiene and Tropical Medicine, Public Health England, University of Cambridge, Merck Sharp & Dohme LLC | Human Papillomavirus Vaccine | 06/24 | 06/24 | | |
NCT04394689: Measles and Rubella Vaccine Microneedle Patch Phase 1-2 Age De-escalation Trial |
|
|
| Completed | 1/2 | 281 | RoW | Measles Rubella Vaccine (MRV-SC), MRV-MNP, PLA-MNP, PLA-SC | Micron Biomedical, Inc, Medical Research Council, Centers for Disease Control and Prevention | Measles, Rubella, Vaccination, Healthy | 11/22 | 12/22 | | |
